A doctor was sentenced to 18 months’ jail on Thursday for administering a substance to a woman as part of an aesthetic treatment that killed her. The ethylenediaminetetraacetic acid (EDTA) was administered too quickly and at too high a concentration, causing 31-year-old Lau Li Ting to develop EDTA toxicity, which led to cardiac arrest and death. Dr Chan Bingyi later concealed the fact that he had ...
A doctor was sentenced to 18 months’ jail on Thursday for administering a substance to a woman as part of an aesthetic treatment that killed her. The ethylenediaminetetraacetic acid (EDTA) was administered too quickly and at too high a concentration, causing 31-year-old Lau Li Ting to develop EDTA toxicity, which led to cardiac arrest and death. Dr Chan Bingyi later concealed the fact that he had administered EDTA to the victim from her family, paramedics and doctors, in what the judge said was...
TOKYO, May 15, 2026--NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in online games, today announced a ten-year renewal to the long-standing partnership with Tencent in publishing Nexon’s flagship PC action RPG Dungeon&Fighter in China. Terms of the agreement were not released.
TOKYO, May 15, 2026--NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in online games, today announced a ten-year renewal to the long-standing partnership with Tencent in publishing Nexon’s flagship PC action RPG Dungeon&Fighter in China. Terms of the agreement were not released.
SusanneB/E+ via Getty Images This article is part of a series that provides an ongoing analysis of the changes made to David Abrams’ 13F portfolio on a quarterly basis. It is based on Abrams’ regulatory 13F Form filed on 05/14/2026. Please visit our Tracking David Abrams’ Abrams Capital Management article for an idea on his investment philosophy and our last update for the fund's moves during Q4 2...
SusanneB/E+ via Getty Images This article is part of a series that provides an ongoing analysis of the changes made to David Abrams’ 13F portfolio on a quarterly basis. It is based on Abrams’ regulatory 13F Form filed on 05/14/2026. Please visit our Tracking David Abrams’ Abrams Capital Management article for an idea on his investment philosophy and our last update for the fund's moves during Q4 2025. This quarter, Abrams’ 13F portfolio value decreased from $5.67B to $4.64B. The number of holdings decreased from 11 to 10. The top three stakes are at ~65% of the 13F portfolio, while the top five holdings are at ~83%. Note 1: Regulatory filings from February show them owning 18.27M shares (40% of the business) of ContextLogic Holdings ( LOGC ). Abrams had a stake in US Salt Parent Holdings LLC, which was acquired by ContextLogic Holdings. The ownership came about as their equity rolled over following the completion of the acquisition. Note 2: David Abrams is a Seth Klarman protégé. Their distinct investment style is elaborated in Seth Klarman’s 1991 classic “Margin of Safety: Risk-Averse Value Investing Strategies for the Thoughtful Investor.” The book is out-of-print, and copies sell for a huge premium. Stake Disposals: Energy Transfer LP ( ET ) : The 1.78% ET stake was established during Q1 2020 at prices between $4.55 and $13.75. There was a ~64% stake increase during Q3 2020 at prices between $5.40 and $7.15 while during Q4 2022 there was a ~20% selling at prices between ~$11 and ~$12.75. Q1 2025 saw another two-thirds reduction at prices between $16.83 and $21.45. The disposal this quarter was at prices between ~$16.25 and ~$20. The stock is now at $20.36. Stake Decreases: Alphabet Inc. ( GOOGL ) : GOOGL is a ~12% of the portfolio position purchased during Q2 2018 at prices between ~$50 and ~$59. There was a ~20% stake increase during Q1 2020 at prices between ~$53 and ~$76. Q4 2022 saw a ~20% selling at prices between ~$83.50 and ~$105. The stake was decreased b...
Joby Aviation (NYSE: JOBY) is an aviation start-up with big ambitions. In a nutshell, it wants to build flying taxis -- electric vertical takeoff and landing (eVTOL) aircraft -- to chauffeur commuters over heavily congested urban streets. If a 10-minute hop in a quiet electric aircraft sounds better than an hour-long slog through on-ground traffic, then you might understand why Morgan Stanley once...
Joby Aviation (NYSE: JOBY) is an aviation start-up with big ambitions. In a nutshell, it wants to build flying taxis -- electric vertical takeoff and landing (eVTOL) aircraft -- to chauffeur commuters over heavily congested urban streets. If a 10-minute hop in a quiet electric aircraft sounds better than an hour-long slog through on-ground traffic, then you might understand why Morgan Stanley once estimated the eVTOL market would be worth about $9 trillion by the middle of this century. Image source: Joby Aviation. Continue reading
(RTTNews) - The China stock market has alternated between positive and negative finishes through the last five trading days since the end of the four-day winning streak in which it had advanced more than 100 points or 2.5 percent. The Shanghai Composite Index now sits just above
(RTTNews) - The China stock market has alternated between positive and negative finishes through the last five trading days since the end of the four-day winning streak in which it had advanced more than 100 points or 2.5 percent. The Shanghai Composite Index now sits just above
OpenAI CEO Sam Altman arrives at the federal courthouse, as the trial in Elon Musk's lawsuit over OpenAI's for-profit conversion continues, in Oakland, California, U.S., May 14, 2026. Manuel Orbegozo | Reuters The first phase of the Musk v. Altman trial concluded proceedings in federal court in Oakland, California, on Thursday after attorneys for Elon Musk and OpenAI presented their closing argume...
OpenAI CEO Sam Altman arrives at the federal courthouse, as the trial in Elon Musk's lawsuit over OpenAI's for-profit conversion continues, in Oakland, California, U.S., May 14, 2026. Manuel Orbegozo | Reuters The first phase of the Musk v. Altman trial concluded proceedings in federal court in Oakland, California, on Thursday after attorneys for Elon Musk and OpenAI presented their closing arguments to the jury. The nine-person jury , which is made up of six women and three men, will begin deliberating on Monday. The jury’s verdict will be advisory, which means Judge Yvonne Gonzalez Rogers will make the final decision on liability. “You must decide the case solely on the evidence before you,” Gonzalez Rogers told the jury Thursday morning, in reading out the formal instructions. “You will recall you took an oath to do so.” Musk sued OpenAI, its CEO Sam Altman and Greg Brockman , the company's president, in 2024, alleging they went back on their commitment to keep the artificial intelligence startup a nonprofit and for unjustly enriching themselves. Musk, who co-founded OpenAI alongside Altman and Brockman in 2015, claims the roughly $38 million he donated to the company was used for unauthorized commercial purposes. During Thursday’s proceedings, Musk’s lawyer, Steven Molo, reiterated his arguments that OpenAI failed to open source its technology, prioritize AI safety and follow nonprofit customs and practices. He also claimed that OpenAI insiders and investors, including Altman, Brockman and Microsoft , enriched themselves at Musk’s expense. Sarah Eddy and William Savitt, attorneys for OpenAI, pushed back on Molo’s statements on Thursday. They said Altman and Brockman never made commitments to Musk about OpenAI’s corporate structure, and that Musk’s donations were spent and used properly. They also noted that the Tesla and SpaceX CEO filed the lawsuit only after launching his competing AI startup, xAI. “He never cared about the nonprofit structure,” Eddy told the ...
(RTTNews) - The Australian stock market is trading modestly higher on Friday, extending the slight gains in the previous session, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving above the 8,650 level, with gains in financial and
(RTTNews) - The Australian stock market is trading modestly higher on Friday, extending the slight gains in the previous session, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving above the 8,650 level, with gains in financial and
Condemnation after Kyiv bears brunt of massive Russian attack wave; warning over military drones too close to Ukrainian nuclear plants. What we know on day 1,542 Continue reading...
Condemnation after Kyiv bears brunt of massive Russian attack wave; warning over military drones too close to Ukrainian nuclear plants. What we know on day 1,542 Continue reading...
Earnings Call Insights: Eton Pharmaceuticals (ETON) Q1 2026 Management View "The first quarter was another great quarter for Eton. We achieved record product sales delivering 73% year-over-year product revenue growth. We launched 2 new major products, DESMODA and HEMANGEOL." (President, CEO & Director Sean Brynjelsen) "Based on the outperformance in the first quarter and the trends we are seeing m...
Earnings Call Insights: Eton Pharmaceuticals (ETON) Q1 2026 Management View "The first quarter was another great quarter for Eton. We achieved record product sales delivering 73% year-over-year product revenue growth. We launched 2 new major products, DESMODA and HEMANGEOL." (President, CEO & Director Sean Brynjelsen) "Based on the outperformance in the first quarter and the trends we are seeing midway through the second quarter, I'm pleased to report that we are raising our full year revenue guidance. We now expect revenue to exceed $120 million, up from our previous guidance of $110 million." (President, CEO & Director Brynjelsen) "Adjusted EBITDA for the quarter was $5.7 million or 24% of revenue." (President, CEO & Director Brynjelsen) "We have already implemented several changes that we believe will improve the therapy experience for patients and providers and add value, including we have streamlined the distribution, shifting to a rare disease-focused model that reduces fragmentation and improves visibility and efficiency during the patient's journey." (President, CEO & Director Brynjelsen) "There are still many variables and uncertainties involved with the launch. However, our preliminary view is that between our free drug patient assistance program, government patients and certain commercial payer contracts we inherited, we estimate that around 60% to 65% of the volume may be near 0 revenue, which should result in an estimated average net price per patient of around $8,000 to $10,000 for a full course of therapy." (President, CEO & Director Brynjelsen) "HEMANGEOL's revenue contribution to second quarter results is expected to be limited." (President, CEO & Director Brynjelsen) "So far, the product launch is meeting my high expectations and we continue to believe it could reach peak sales of $30 million to $50 million." (President, CEO & Director Brynjelsen) "On June 1, Judy Matthews will take over as CFO." (President, CEO & Director Brynjelsen) "First quarte...
Pla2na/iStock via Getty Images Written by Nick Ackerman, co-produced by Stanford Chemist We saw some substantial volatility recently, and that gives us another good look at how Roundhill Innovation-100 0DTE Covered Call Strategy ETF ( QDTE ) has held up. This is important because the last time we covered the fund, it was coming out of last year's tariff-driven market correction. We saw QDTE's "wor...
Pla2na/iStock via Getty Images Written by Nick Ackerman, co-produced by Stanford Chemist We saw some substantial volatility recently, and that gives us another good look at how Roundhill Innovation-100 0DTE Covered Call Strategy ETF ( QDTE ) has held up. This is important because the last time we covered the fund, it was coming out of last year's tariff-driven market correction. We saw QDTE's "worst-case scenario play out," but this time we saw something different. The market rebounded sharply, but not to the same volatile degree we did last year. With that said, since our last update , the fund has delivered an attractive total return. Though the share price has declined since, it was entirely offset by the massive distribution that the fund pays. QDTE Returns Since Prior Update (Seeking Alpha) I believe that QDTE can still remain an attractive fund to consider for income-focused investors, but there are some caveats, and it won't be right for all investors. QDTE Basics Dividend Frequency: Weekly Dividend Yield: 27.1% (-0.59% SEC yield) Expense Ratio: 0.97% Leverage: N/A Managed Assets: $828.18 million Structure: Active ETF The fund sponsor describes QDTE as "The first ETF to utilize zero days to expiry ("0DTE") options on an innovation index (the "Innovation-100 Index" as defined in the Fund Prospectus). QDTE seeks to provide overnight exposure to the Innovation-100 Index and generate income each morning by selling out-of-the-money 0DTE calls on the Index." Performance With Latest Market Volatility When looking at performance comparisons, I will be putting QDTE up against the Invesco QQQ Trust ( QQQ ) as its plain-vanilla benchmark. I'll also be including the results of the NEOS Nasdaq-100 High Income ETF ( QQQI ). QQQI uses a flexible overwrite strategy that can float around 50%-as of writing, the overwrite was around 56.5%. This is also with a laddered approach, meaning they use a couple of different contracts at different strike prices. They also use a more tra...